BALTIMORE – The key to predicting how someone is affected by sleep loss may be found in microRNAs (miRNAs), according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania. Many studies connect sleep loss with cancer, cardiovascular disease, Alzheimer’s, and other disorders, and it is well known that sleep loss negatively affects cognitive performance. However, those adverse effects are experienced differently from person to person, and little is known about how to accurately predict and detect these individual sleep-deprivation deficits.
This study is the first to find that microRNAs in the blood are changed by total sleep deprivation (TSD) for 39 hours, and by psychological stress, and can predict the resulting cognitive performance in adults. The authors say the findings can be used to identify who is most at risk for the negative effects of sleep deprivation, and thus should receive medical assistance to prevent those effects.
MiRNAs are small non-coding RNAs and are key regulators of gene expression, which guides information in a gene to be made into a functional protein. MiRNAs typically repress expression of their target messenger RNAs, preventing translation into proteins.
The findings (#0012) will be presented at SLEEP 2018, the 32nd Annual Meeting of the Associated Professional Sleep Societies LLC (APSS) at the Baltimore Convention Center on Sunday and Monday, June 3 and 4.
In the study, 32 healthy adults participated in a five-day experiment consisting of two, 8-hour baseline nights, followed by 39 hours of total sleep deprivation (TSD), in which they were not allowed to sleep, and followed by two, 8-to-10-hour recovery nights.
Subjects underwent testing for attention, memory, and cognitive throughput, i.e., how fast and accurate the brain performs of cognitive tests, were administered throughout the experiment to measure cognitive performance. Blood samples were taken at six time points and miRNAs from plasma were analyzed.
Compared to the pre-study time point, 10 miRNAs showed changes in their expression level in subjects who experienced TSD alone compared to 18 miRNAs with expression level changes in these subjects when they experienced TSD and psychological stress.
Notably, from the miRNA blood sample taken before the study began, 14 miRNAs reliably predicted behavioral attention performance during TSD, 7 miRNAs reliably predicted cognitive throughput performance during TSD and 10 miRNAs reliably predicted memory performance.
“These findings show for the first time that miRNAs can track responses to total sleep deprivation and its detrimental combination with psychological stress and predict robust individual differences in various types of cognitive performance,” said senior author Namni Goel, PhD, an associate professor of Psychology in Psychiatry. “As such, miRNAs are viable biomarkers of sleep deprivation, psychological stress, and cognitive vulnerability in humans and can be used to identify individuals ahead of time who are in need of countermeasures or interventions such as caffeine or naps to mitigate or prevent impairments associated with insufficient sleep.”
This work was supported by NASA (NNX14AN49G).
The findings will be presented June 3, 1-3 pm, in room 325 and the poster session (poster #160) Sunday, June 3, 5-7 pm, and on Monday, June 4, 11-11:15 am in Room 322.
In addition to Goel, the other authors on the study, all from the Children’s Hospital of Philadelphia, include lead author Michelle Zajko, and Deanne Taylor, Jiah Pearson-Leary, and Seema Bhatnagar.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.